A cocaethylene finding and an ethanol result are different measurements. In an 81-patient clinical study, one patient in the ethanol-negative group had cocaethylene detected in blood. That observation cautions against defining exposure history solely by contemporaneous ethanol detection, but it does not establish an exact drinking time, dose or postmortem explanation.
The groups were defined by the measured ethanol result
Zucoloto and colleagues enrolled adults evaluated for suspected cocaine or crack intoxication, selected through a positive urine cocaine screen. Three of 84 initially assessed patients were excluded for exposure to other stimulants. Among the remaining 81, Group A contained 62 without positive blood ethanol, while Group B contained 19 with positive blood ethanol.
These labels did not perfectly separate people who had and had not consumed alcohol. Thirty of 62 in Group A reported alcohol association, compared with 14 of 19 in Group B. The difference in self-report proportions was not statistically significant at the prespecified 5% level (P = 0.053). An ethanol-negative classification should therefore not be paraphrased as a verified history of cocaine-only use.
Cocaethylene detection and concentration had different denominators
Cocaethylene was detected in one of 62 Group A patients and four of 19 Group B patients. The single Group A value was 0.22 μg/mL. In the four positive Group B specimens, the mean was 0.42 ± 0.38 μg/mL, with a range of 0.10–0.87 μg/mL.
Detection was more frequent in Group B (P = 0.002), but the between-group concentration difference was not significant. Comparing one positive observation with four does not establish a dependable quantitative rule for alcohol exposure. The paper discusses cocaethylene as a product of cocaine–ethanol interaction; its observed detection pattern does not independently date that interaction.
Collection timing limits interpretation
Blood and urine were collected with the initial clinical assessment. Blood samples of approximately 3 mL were taken into EDTA tubes. The report does not specify a uniform anatomical collection site or provide a complete storage timeline. Time from exposure was known for only 23 patients overall, including six in Group B. The Group B mean was 4.7 ± 4 hours, range 1–12, compared with 7.2 ± 5.4 hours in 17 Group A patients.
Those selected timing subsets cannot explain every discordant result. The design did not serially sample all patients to validate a time-since-use equation.
The analytical and statistical boundaries matter
The initial urine test was an immunoassay for benzoylecgonine, cutoff 150 ng/mL. Cocaethylene in blood was measured separately by HPLC with diode-array detection after liquid-liquid extraction. The article refers to a previously published method and does not supply a complete set of numerical blood-assay validation parameters. A urine screen is not confirmation of a blood cocaethylene concentration.
Clinical severity also requires careful reporting: mean symptom scores differed nonsignificantly between the groups in the initial analysis (P = 0.103). Removing two Group A outliers produced P = 0.008. Both analyses matter; the latter should not be described as the sole, unqualified study result or proof that cocaethylene caused greater severity.
What the finding does not establish after death
This was living-patient research, not an investigation of ethanol production during decomposition. It did not validate cocaethylene as a postmortem formation discriminator, determine a fatal concentration, or reconstruct impairment. A death investigation requires its own specimen history, analytical validation and case evidence.
The broader distinction between the time of collection and the later interpretation is addressed in hospital ethanol specimens in death investigations. The observed discordance here remains a clinical finding, with the limits of that design.
Primary source
Zucoloto AD, Eller S, de Oliveira TF, Wagner GA, Fruchtengarten LVG, de Oliveira CDR, Yonamine M. Relationship between cocaine and cocaethylene blood concentration with the severity of clinical manifestations. American Journal of Emergency Medicine. 2021;50:404–408. doi:10.1016/j.ajem.2021.08.057.
Leave a Reply